Inclisiran : Small Interfering Ribonucleic Acid Injectable for the Treatment of Hyperlipidemia
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved..
Elevated plasma lipid levels, especially low-density lipoprotein, are correlated with atherosclerotic cardiovascular disease (ASCVD) and increased risk of ischemic heart disease and stroke. Statins are first-line agents for reducing low-density lipoprotein cholesterol (LDL-C) and the risk of major cardiovascular events, but patients with a genetic susceptibility or established ASCVD oftentimes remain subtherapeutic on statin therapy alone. Biotechnological advancements in medication therapy have led to the development of inclisiran, a recently approved twice-yearly injectable agent to help patients with heterozygous familial hypercholesterolemia and clinical ASCVD on a maximally tolerated statin to reach LDL-C targets. Inclisiran has demonstrated robust LDL-C reduction in clinical trials in combination with a favorable safety profile; however, the effect on cardiovascular clinical outcomes still remains under evaluation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Cardiology in review - 30(2022), 4 vom: 06. Juli, Seite 214-219 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hughes-Hubley, Frances [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ALN-PCS |
|---|
| Anmerkungen: |
Date Completed 08.06.2022 Date Revised 03.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1097/CRD.0000000000000452 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341886564 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341886564 | ||
| 003 | DE-627 | ||
| 005 | 20231226012813.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/CRD.0000000000000452 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1139.xml |
| 035 | |a (DE-627)NLM341886564 | ||
| 035 | |a (NLM)35666780 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hughes-Hubley, Frances |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Inclisiran |b Small Interfering Ribonucleic Acid Injectable for the Treatment of Hyperlipidemia |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.06.2022 | ||
| 500 | |a Date Revised 03.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved. | ||
| 520 | |a Elevated plasma lipid levels, especially low-density lipoprotein, are correlated with atherosclerotic cardiovascular disease (ASCVD) and increased risk of ischemic heart disease and stroke. Statins are first-line agents for reducing low-density lipoprotein cholesterol (LDL-C) and the risk of major cardiovascular events, but patients with a genetic susceptibility or established ASCVD oftentimes remain subtherapeutic on statin therapy alone. Biotechnological advancements in medication therapy have led to the development of inclisiran, a recently approved twice-yearly injectable agent to help patients with heterozygous familial hypercholesterolemia and clinical ASCVD on a maximally tolerated statin to reach LDL-C targets. Inclisiran has demonstrated robust LDL-C reduction in clinical trials in combination with a favorable safety profile; however, the effect on cardiovascular clinical outcomes still remains under evaluation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a ALN-PCS |2 NLM | |
| 650 | 7 | |a Anticholesteremic Agents |2 NLM | |
| 650 | 7 | |a Cholesterol, LDL |2 NLM | |
| 650 | 7 | |a Hydroxymethylglutaryl-CoA Reductase Inhibitors |2 NLM | |
| 650 | 7 | |a RNA, Small Interfering |2 NLM | |
| 700 | 1 | |a Iskander, Mina |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng-Lai, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Frishman, William H |e verfasserin |4 aut | |
| 700 | 1 | |a Nawarskas, James |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cardiology in review |d 1997 |g 30(2022), 4 vom: 06. Juli, Seite 214-219 |w (DE-627)NLM09257050X |x 1538-4683 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2022 |g number:4 |g day:06 |g month:07 |g pages:214-219 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/CRD.0000000000000452 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2022 |e 4 |b 06 |c 07 |h 214-219 | ||